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Abstract   
People with Down syndrome (DS) have a neurodevelopmentally distinct brain and invariably 
develop amyloid neuropathology by age 50. This cross-sectional study aimed to provide a 
detailed account of DS brain morphology and the changes occuring with amyloid 
neuropathology. Forty-six adults with DS underwent structural and amyloid imaging—the 
latter using Pittsburgh Compound–B (PIB) to stratify the cohort into PIB–positive (n=19) and 
PIB–negative (n=27). Age-matched controls (n=30) underwent structural imaging. Group 
differences in deep grey matter volumetry and cortical thickness were studied. PIB-negative 
people with DS have neurodevelopmentally atypical brain, characterised by 
disproportionately thicker frontal and occipitoparietal cortex and thinner motor cortex and 
temporal pole with larger putamina and smaller hippocampi than controls. In the presence of 
amyloid neuropathology, the DS brains demonstrated a strikingly similar pattern of posterior 
dominant cortical thinning and subcortical atrophy in the hippocampus, thalamus and the 
striatum, to that observed in non-DS Alzheimer’s disease. Care must be taken to avoid 
underestimating amyloid–associated morphological changes in DS due to disproportionate 
size of some subcortical structures and  thickness of the cortex. 
Keywords: Alzheimer’s disease, amyloid, cortical thickness, Down syndrome, grey matter 
volume 
 
Abbreviations 
AD – Alzheimer’s disease; CAMCOG - Cambridge Examination for Mental Disorders in 
Older people with DS and Others with Intellectual Disabilities; DS – Down syndrome; MRI – 
magnetic resonance imaging; PET – positron emission tomography; PIB – Pittsburgh 
Compound-B.
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1 Introduction 
People with Down syndrome (DS) are known to have developmentally altered brain structure 
caused by trisomy of chromosome 21. Children with DS present with delayed maturation of 
the central nervous system, which has been linked to prenatal arrest of neurogenesis and 
synaptogenesis (Schmidt-Sidor et al., 1990; Wisniewski, 1990). Post–mortem studies in 
adults with DS have found several brain abnormalities, including reduced gross brain weight, 
a lower number and depth of cerebral sulci, enlarged ventricles and hypoplasia of several 
brain structures such as the brainstem, cerebellum, frontal and temporal lobes. In contrast, 
subcortical structures are shown to be relatively preserved (de la Monte and Hedley-Whyte, 
1990; Dierssen, 2012; Dierssen and Ramakers, 2006; Lott and Dierssen, 2010; Delabar et al., 
2006). Imaging studies in adults with DS have corroborated the post–mortem findings by 
showing widespread cerebral hypoplasia and ventricular enlargement in comparison to 
typically developing individuals [Supplementary Table 1, Kesslak et al. (1994); Raz et al. 
(1995); Roth et al. (1996); Frangou et al. (1997); Aylward et al. (1997b); Pearlson et al. 
(1998); Aylward et al. (1997a); Aylward et al. (1999); Pinter et al. (2001); Krasuski et al. 
(2002); Teipel et al. (2003); White et al. (2003); Prasher et al. (2003); Teipel et al. (2004); 
Beacher et al. (2009); Beacher et al. (2010); Koran et al. (2014)]. The vast majority of 
neuroimaging studies, however, are based on region–of–interest volumetry, which is only 
able to detect volumetric changes in predetermined regions. There is a need to study the 
structural morphology of the whole DS brain in a more unbiased way. 
In addition to the developmental abnormalities, people with DS are at high risk for early–
onset Alzheimer’s disease (AD) and have been found to deposit β–amyloid plaques from 
about 40 years of age (Mann et al., 1990; Mann et al., 1984; Annus et al., 2016). Similar to 
sporadic AD, significant amyloid binding with PET is found before any signs of cognitive or 
functional decline in DS (Landt et al., 2011; Handen et al., 2012; Hartley et al., 2014; Annus 
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et al., 2016). Yet previous structural imaging studies (see Supplementary Table 1) have 
aimed to characterise the developmental alterations of the adult DS brain by studying non–
demented individuals; such studies are, therefore, potentially confounded through the 
aggregation of amyloid positive and negative participants. For instance, four previous 
neuroimaging studies (Pearlson et al., 1998; Aylward et al., 1999; Prasher et al., 2003; 
Beacher et al., 2009) aimed to characterise cerebral atrophy associated with AD in DS by 
comparing cognitively stable individuals to those with a clinical diagnosis of dementia. It is 
highly likely, however, that a sizable proportion of cognitively stable individuals already had 
amyloidosis and it is known from the general population (Desikan et al., 2010; Dickerson et 
al., 2009; Dickerson and Wolk, 2011) that abnormalities in cortical structure occur at 
presymptomatic stages of AD. As such, the present cross-sectional study aimed to 
characterise the morphology of the adult DS brain in the absence of amyloid deposits and to 
describe the changes seen in the presence of fibrillar β–amyloid neuropathology. 
 
2 Materials and methods 
2.1 Study design and participants 
Forty–six adults with DS and 30 typically developing participants (controls) took part in the 
present study. The DS cohort is the same as that reported in a previous amyloid PET study 
(Annus et al., 2016) with the exception of two amyloid negative and one amyloid positive 
participant, whose magnetic resonance imaging (MRI) scans were of inferior quality (motion 
artefact evident on visual inspection) and hence unsuitable for reliable morphometric 
analysis. Adults with DS were identified via clinical and social services for people with 
intellectual disabilities in England and Scotland and via the DS Association (UK), whereas 
volunteers with typical neurodevelopment were recruited from the local community via 
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advertisement. Control participants were screened to exclude neurological and major 
psychiatric illness and developmental disorders. All study participants were screened for 
contraindications to MRI. Written consent was obtained from typically developing controls 
and all adults with DS with capacity to consent. Verbal assent was obtained from participants 
with DS lacking capacity and a written assent was provided by an appointed consultee, in 
accordance with the UK Mental Capacity Act (2005). Ethics and research and development 
approvals were granted by the National Research Ethics Committee of East of England – 
Norfolk and Cambridgeshire and Peterborough NHS Foundation Trust, respectively. 
 
2.2 Clinical assessments 
All participants with DS had previously received a clinical diagnosis of DS based on the 
characteristic phenotype with full trisomy 21 confirmed in 33 DS participants by 
karyotyping. All participants with DS were assessed for dementia using the Cambridge 
Examination for Mental Disorders in Older people with DS and Others with Intellectual 
Disabilities informant interview as described previously (Annus et al., 2016) and allocated 
into categories of “Stable cognition”, “Cognitive decline” and “Dementia”. Dementia was 
diagnosed in accordance with the International Classification of Diseases-10 criteria and 
diagnosis of “Cognitive decline” was given to participants with evidence of functional 
decline in one or more cognitive domains, while insufficient to satisfy the full criteria for 
dementia. All DS participants, except three who had severe dementia and were untestable, 
were administered the cognitive function assessment – CAMCOG – part of the Cambridge 
Examination for Mental Disorders in Older people with DS and Others with Intellectual 
Disabilities. With the exception of one demented individual who was receiving Donepezil, no 
participants were using anti-dementia medications. 
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2.3 Magnetic resonance imaging acquisition 
All participants underwent an anatomical MRI scan on a Siemens Verio 3T scanner with 12 
channel head coil (Siemens AG, Erlangen, Germany) using the 3D T1–weighted 
magnetisation–prepared, rapid gradient–echo pulse sequence with the following parameters: 
repetition time / echo time / inversion time / flip angle = 2300ms/ 2·98ms/ 900ms/ 9°, 
256x240x176 matrix dimensions, and 1x1x1 mm3 voxel size. Receiver bandwidth and echo 
spacing were 240 Hz/pixel and 7.1 ms, respectively and parallel acceleration was disabled. 
The imaging protocol included whole–brain, T2–weighted, half–Fourier acquisition, single–
shot turbo spin echo sequence (repetition time/ echo time/ flip angle/ turbo factor = 1500ms/ 
79ms/ 150°/ 256; 0.9x0.7x4.0 mm3 voxel size) to assess for vascular pathology and incidental 
lesions. For all acquisitions, the field of view was aligned in stereotactic space, with the axial 
plane aligned to the anterior commissure – posterior commissure line and the sagittal plane to 
the interhemispheric fissure. 
 
2.4 Positron emission tomography using [11C]–Pittsburgh Compound–B 
Details of the PIB PET data acquisition and processing have been published previously 
(Annus et al., 2016). Briefly, PIB PET images were acquired in 3D mode on a GE Advance 
scanner (General Electric Medical Systems, Milwaukee, WI, USA) for 90 minutes post–PIB 
injection in 58 frames. Only participants with DS were assessed for amyloid. Cortical 
regional PIB analysis was based on Brodmann areas, whereas subcortical regions of interest 
were based on deep grey matter parcellations using FIRST (Patenaude et al., 2011) and 
included the striatum (caudate nucleus and putamen), amygdala, thalamus, and hippocampus. 
For each region of interest, non–displaceable binding potential was obtained using a basis 
function implementation of the simplified reference tissue model (Gunn et al., 1997) with 
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superior cerebellar grey matter as reference region. PIB positive and PIB negative groups 
were assigned on the basis of striatal non–displaceable binding potential, which had 
previously revealed a bimodal distribution with clear separation of positive and negative 
groups (Annus et al., 2016). Of the 46 participants with DS, 19 were PIB–positive.  
 
2.5 Image processing 
2.5.1 Cortical thickness analysis 
Cortical thickness analysis was conducted using FreeSurfer (v5.3, available from 
https://surfer.nmr.mgh.harvard.edu). The detailed procedure for surface reconstruction and 
estimation of cortical thickness has been described previously (Dale et al., 1999; Fischl et al., 
1999; Fischl and Dale, 2000). Image processing involved automated non-uniformity bias 
correction, skull stripping, segmentation of the white matter and estimation of the grey/white 
matter boundary. Segmented and skull–stripped data of all participants were visually 
inspected for parcellation errors and topological defects in the grey/white matter boundary 
were manually corrected. The grey/white boundary served as a starting point for a deformable 
surface algorithm to compute the grey/white and pial surfaces, from which cortical thickness 
is calculated as the closest distance from the grey/white matter boundary to the pial surface at 
each vertex on the tessellated surface. Thickness measurements were mapped on the inflated 
surface of each participant’s brain reconstruction for visualisation of data across the entire 
cortical surface. The thickness measurements using this technique have been shown to be 
both valid (Rosas et al., 2002) and reliable (Dickerson et al., 2008). Each participant’s brain 
was then morphed and aligned to a spherical common surface template using a high–
resolution surface–based averaging technique that aligns cortical folding patterns by 
individual sulci and gyri. Prior to analysis, the data was smoothed with a 25mm full–width at 
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half–maximum Gaussian kernel, the rationale for using a large kernel size has been published 
previously (Diaz-de-Grenu et al., 2014). Statistical analysis was performed using the QDEC 
module implemented in FreeSurfer. For each hemisphere, General Linear Model was applied 
to estimate variations in cortical thickness at each vertex of the surface. Statistical surface 
maps were created using a vertex–wise statistical threshold of p<0.05 corrected for false-
discovery rate at q<0.05. Covariate of interest analysis in FreeSurfer demonstrated no 
significant gender or total intracranial volume (TIV)  specific regional differences in cortical 
thickness between PIB–negative group and neurotypical controls, resulting in the exclusion 
of both covariates from the statistical models (data not shown). Furthermore, β–amyloid has 
been shown to be a function of age in people with DS (Annus et al., 2016) and by controlling 
for age, the true effects of Alzheimer's disease would be removed. A subgroup analysis was 
conducted in age–matched PIB–negative and PIB–positive group by including all individuals, 
who were in the age bracket of 39–48 years representing the time from first evidence of 
amyloid binding to the whole cohort being positive on PIB PET [for detailed results, see 
Annus et al. (2016)]. 
 
2.5.2 Deep grey matter volumetry 
Deep brain regions of interest were defined by constructing a mask of these structures using 
FIRST [Patenaude et al. (2011), available from: http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST]. 
Individual structural neuroimaging data was registered by a two–stage affine transformation 
to a standard Montreal Neurological Institute space with 1mm3 resolution using 12 degrees of 
freedom, after which the registered data was fitted with ‘a surface mesh’ modelled using a 
multivariate Gaussian model based on the shape and intensity information from the 
normalised T1–images (Patenaude et al., 2011). The segmentation was performed on all 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
subcortical structures using the run_first_all wrapper with default settings and visually 
inspected for errors and misregistrations. As a result, nucleus accumbens, brain stem and 
globus pallidus were excluded from the analyses due to their small size, poor segmentation 
and high frequency of calcified lesions, respectively. Volumes of the structures of interest 
(putamen, caudate nucleus, thalamus, hippocampus and amygdala) for each hemisphere were 
calculated and corrected for TIV (Jack et al., 1989). To limit the number of statistical tests, 
volumes of the left and right hemisphere structures were averaged for group comparisons. 
TIV and total brain volumes were determined by summing the relevant tissue classes using 
Statistical Parametric Mapping (Pengas et al., 2009). All calculated volumes were normally 
distributed across study groups (Shapiro–Wilk test, all p>0.05), thus parametric tests in SPSS 
Statistics 22.0 (IBM, Corp.) were implemented for statistical analyses. Between–group 
differences were assessed using One-way ANOVA, whereas independent group and 
correlation analyses were conducted using Independent sample t–test (all two–tailed) and 
Pearson’s correlation test, respectively. The relationship between categorical variables was 
assessed using Chi–squared test. A significance level of p<0.05 was used for all inferences 
with results reported as mean and standard deviation. 
 
3. Results 
3.1 Demographics and summary measures 
Participant demographics are provided in Table 1. Participants in the PIB–negative group 
were significantly younger than controls (t(48)= –4.311, p<0.001) and the PIB–positive 
group (t(37)= –6.722, p<0.001), whereas controls and PIB–positive group were of similar 
ages (t(47)=1.491, p=0.143). The Control group had significantly larger TIV than PIB–
negative (t(55)=7.370, p<0.001) and PIB–positive (t(47)=5.535, p<0.001) individuals with 
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DS, while there was no difference in TIV between the two DS groups (t(44)=0.735, p=0.466). 
The PIB–positive group had significantly lower TIV–corrected total brain volume than PIB–
negative group (t(44)= –5.304, p<0.001), as well as controls (t(47)= –4.444, p<0.001). PIB–
negative and control groups had similar TIV–corrected total brain volume (t(55)= –0.189, 
p=0.850; Fig. 3). Furthermore, on average the isocortex in the PIB–negative group was 4.3% 
thicker than in controls and 4.9% thicker than in the PIB–positive group, whereas PIB–
positive and control group had similar mean global cortical thickness (0.56% lower in PIB–
positive, Supplementary Fig. 1). No differences were observed in the cognitive function test 
CAMCOG between PIB–negative and PIB–positive groups (t(41)= –1.057, p=0.297). Note, 
however, that three individuals in the PIB–positive group were untestable because of 
dementia—for this reason analyses were also run excluding these three individuals in order to 
contrast PIB–positive and PIB–negative participants matched for CAMCOG performance. 
Excluding these three severely demented individuals did not influence the findings reported 
for the overall PIB–positive group (Table 1). Interestingly, even the cognitively stable 
participants in the PIB–positive group had significantly lower TIV–corrected total brain 
volume (1,087.98 ± 72.82 cm3 vs 1,148.05 ± 31.27 cm3, respectively; t(29)= –3.232, 
p=0.003) and lower mean global cortical thickness (2.58 ± 0.10 mm vs 2.68 ± 0.10mm, 
respectively; t(29)=2.425, p=0.022) than cognitively stable participants in the PIB–negative 
group.  
 
 
[TABLE 1 HERE] 
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3.2 Cortical thickness 
3.2.1 PIB–negative Down syndrome vs Controls 
The vertex–wise analysis in the PIB–negative group compared with controls demonstrated 
highly significant cortical thinning in the precentral gyrus; significant thinning was also 
found in the temporal pole with additional small areas in subgenual anterior cingulate and 
retrosplenial cortex (Fig. 1). Widespread cortical thickness increases relative to controls were 
evident in medial and lateral prefrontal cortex; parietal, precuneus and posterior cingulate 
cortex; postcentral gyrus; occipital and postero-inferior temporal cortex. Controlling for age 
differences between PIB–negative and Control group did not alter the main findings (see 
Supplementary Fig. 2). 
  
 
[FIGURE 1 HERE] 
 
 
 
3.2.2 PIB–positive Down syndrome vs PIB–negative Down syndrome 
Vertex–wise analysis of cortical thickness in the PIB–positive compared to PIB–negative 
group revealed large confluent clusters of cortical thinning in parieto–temporo-occipital 
cortices, posterior cingulate and precuneus cortices along with some small and scattered 
changes in prefrontal areas. The extent of cortical thinning was more marked in the right 
hemisphere. In contrast, there were some small, weakly significant areas of greater thickness 
in the PIB–positive group in the right sub-genual cortex and left precentral gyrus (Fig. 2). 
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Removal of the three PIB-positive DS individuals, who were too advanced to complete the 
CAMCOG, did not alter the reported findings (data not shown). While PIB–negative group 
was significantly younger than PIB–positive, matching the groups for age is problematic 
because, by definition, transition to amyloid positivity is a function of age in people with DS 
[see Annus et al. (2016)]. Nonetheless, the age bracket from 39 to 48 years contained an 
overlap of PIB–positive (n=9) and PIB–negative (n=13) participants that were matched for 
age (t(20)=1.481, p=0.154). Reducing the power by only looking at this subgroup meant that 
the significance of the changes diminished, however at p(uncorr)<0.05 a similar atrophy 
pattern to that seen in the full cohort contrast was evident (Supplementary Fig. 3). 
 
 
[FIGURE 2 HERE] 
  
 
 
3.3 Deep grey matter volumetry 
Compared to controls, the PIB–negative group had significantly larger TIV–corrected 
putamina (t(55)= 5.351, p<0.001) and smaller hippocampi (t(55)=4.951, p<0.001), whereas 
no volumetric differences were identified in the caudate nucleus and thalamus. The results 
remained unaltered, when corrected for differences in age between the two groups (data not 
shown).  Relative to the PIB–negative group, the PIB–positive group demonstrated 
significantly atrophic caudate nucleus (t(44)=2.323, p<0.05), putamen (t(44)= 5.52, p<0.001), 
thalamus (t(44)= 3.277, p=0.01) and hippocampus (t(44)= 4.258, p<0.001), whereas only 
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thalamic (t(47)= 4.289, p<0.001) and hippocampal volumes (t(47)= 8.361, p<0.001) were 
smaller when compared to controls. There were no significant differences in the TIV–
corrected volumes of amygdala (F(3,75)= 0.878, p=0.42) across the three groups (Fig. 3). 
Furthermore, the inclusion of three severely demented individuals in the PIB–positive group, 
who were untestable on the CAMCOG assessment, had no impact on the deep grey matter 
volumetry findings in the PIB–positive group (unfilled circles, Fig. 3). 
 
 
 
[FIGURE 3 HERE] 
 
 
 
4 Discussion 
The present study demonstrated a distinct neurodevelopmental phenotype of the DS brain 
with evidence of a thicker cortical ribbon particularly in the frontal and occipital lobes and 
thinner motor cortex. Development of fibrillar β–amyloidosis in people with DS is associated 
with a widespread posterior cortical thinning and subcortical atrophy in a pattern highly 
concordant with that seen in sporadic (Dickerson et al., 2009; Fjell et al., 2014; Jack et al., 
2009) and familial AD (Fortea et al., 2010; Cash et al., 2013). This study is the first of its 
kind to provide a comprehensive analysis of the cortical and subcortical landscape of the 
adult DS brain in groups clearly defined according to amyloid status.  
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4.1 The structure of the Down syndrome brain without amyloid 
It is expected that the DS brain differs qualitatively from that of the typically-developing 
population. The aim of the contrast of amyloid-negative DS to healthy controls was to map 
these differences and, therefore, to aid interpretation of the changes that then occur in the DS 
brain in the presence of amyloid. With a mean age of 46 years, it was considered highly 
unlikely that the control group would be contaminated with amyloid-positive participants. In 
line with previous work (see Supplementary Table 1), adults with DS presented with 
significantly lower TIV compared to neurotypical controls. The current findings indicate, 
however, that the DS brain is not simply a downscale model of the typically developed brain 
but has a distinct topography of regions that are disproportionally smaller or larger with 
respect to the smaller brain size. In the absence of amyloid, the brain of people with DS is 
characterised by atypically and disproportionally thicker cortex in the frontal, parietal, 
occipitotemporal and posterior cingulate areas. Furthermore, people with DS have 
neurodevelopmentally thinner motor cortices and temporal poles. The present findings are in 
line with a recent report of increased cortical thickness in the frontal, parietal and occipital 
lobes in children and young adults with DS [mean age 15 years, range 5–24 years; Lee et al. 
(2015)], demonstrating that a largely thicker cortex is present already in childhood and 
persists into adulthood in individuals with DS. However, the authors only focused on the 
pattern of thicker cortex in the DS youth in comparison to typically developing youth and did 
not investigate the reverse contrast, thus possibly missing the pattern of cortical thinning 
described in the present study. Interestingly, the regions that are atypically thicker in DS are 
characterised by pronounced cortical thinning during brain development in adolescents 
without trisomy 21 (Vandekar et al., 2015). This suggests a delay in the cortical thinning in 
DS and that the abnormalities in the development and maturation of the cortex extend beyond 
early development well into adulthood.  
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In deep grey matter structures, the most striking differences between people with DS and 
neurotypical controls was in the striatum – specifically that the putamen was 
disproportionately enlarged in amyloid negative adults with DS. Disproportionally greater 
volume of the putamen has been previously found in a morphometry study of children 
(Menghini et al., 2011) and in non–demented adults with DS (Beacher et al., 2010; Aylward 
et al., 1997b), when compared to typically developing individuals. This again points to a 
neurodevelopmental origin of the observed structural enlargement, in line with the findings of 
increased cortical thickness as a result of abnormal cortical development and maturation in 
DS. 
The hippocampi were disproportionally smaller in PIB–negative individuals with DS 
compared to neurotypical controls – a finding consistent with previous in vivo volumetry 
reports (Menghini et al., 2011; Smigielska–Kuzia et al., 2011; Kesslak et al., 1994; Raz et 
al., 1995; Krasuski et al., 2002; White et al., 2003). As the current study was cross-sectional, 
it cannot address whether this reduction in hippocampal volume in adults with DS is 
developmental (hypoplasia) or acquired (atrophy). It would seem, however, to almost 
certainly represent hypoplasia because past studies have found decreased hippocampal 
volume in adults under the age of 30 years (Raz et al., 1995), as well as in adolescents 
(Menghini et al., 2011) and children (Smigielska–Kuzia et al., 2011) with DS. Although 
these past studies did not include amyloid imaging, it seems reasonable to assume, based on 
amyloid PET (Annus et al., 2016) and pathology (Mann and Esiri, 1989) studies, that such 
participants would have been amyloid negative. The rest of the subcortical structures, 
including the thalamus and the amygdala, did not exhibit any DS specific characteristics in 
the absence of PIB binding and were neurodevelopmentally proportional to those of typically 
developing controls. 
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4.2 The PIB positive Down syndrome brain 
A significant reduction in TIV–corrected total brain volume was observed in the PIB–positive 
group, when compared to the PIB–negative group. In addition to marked volumetric 
differences, amyloid positive individuals also presented with significantly lower mean global 
cortical thickness than their amyloid negative counterparts. This reduction in both volume 
and cortical thickness was significant even in the cognitively stable PIB–positive participants, 
demonstrating that, in keeping with sporadic (Becker et al., 2011; Aizenstein et al., 2008) and 
familial AD (Klunk et al., 2007; Villemagne et al., 2009), volume loss and cortical thinning 
is measurable before any clinical signs of cognitive decline in people with DS. The neocortex 
of PIB–positive adults with DS exhibited a pattern of posterior dominant cortical thinning 
mapped to the parieto–temporo-occipital cortices laterally and to the medial posterior 
cingulate and precuneus cortices. This pattern of reduced thickness  in DS was highly similar 
to that observed in sporadic and familial AD (Boxer et al., 2003; Cash et al., 2013; Du et al., 
2007; Fjell et al., 2014; Gili et al., 2011). The volumes of putamen and caudate were 
significantly lower in PIB–positive individuals with DS compared to either the PIB–negative 
group or typically developing controls. This result highlights the importance of amyloid 
stratification in DS – the striatal volume reduction would be missed entirely if one examined 
volumetric changes in PIB–positive DS only in comparison to a neurotypical control group. 
The striatum has been receiving increasing interest in the field of AD, particularly as it has 
been shown to be the first site of PET amyloid binding in the familial forms of early onset 
AD (Klunk et al., 2007; Koivunen et al., 2008; Remes et al., 2008; Villemagne et al., 2009; 
Pievani et al., 2013) and recently in people with DS (Annus et al., 2016; Handen et al., 
2012).   
The PIB–positive group demonstrated significant reduction in the thalamic volume, when 
compared to amyloid negative individuals. PIB positivity was also associated with marked 
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hippocampal volume reduction, when contrasted to PIB–negative DS group. As already 
noted, the TIV–corrected hippocampal volumes in PIB–negative individuals with DS were, in 
turn, significantly smaller than controls. Hippocampal atrophy is an expected finding in AD, 
though it is interesting to note that the effect size was comparable to that for putaminal 
atrophy (Fig. 3) in the amyloid–positive DS group. Given that many of the amyloid–positive 
individuals in the present series were asymptomatic, these findings suggest that atrophy 
becomes measurable very early after the conversion to amyloid positivity, although this 
hypothesis would need to be proven in a longitudinal sample. 
 
4.3 Limitations 
The present study is the first in characterising the brain morphology in neuropathologically 
clearly defined groups of amyloid positive and negative adults with DS. There were, 
however, inevitable age differences between the PIB–negative and PIB–positive group as a 
result of age–dependent threshold of amyloidosis in the DS population (Annus et al., 2016). 
As such, it is not possible to control for the differences in age in the statistical models without 
removing the effects of amyloid. Although the lack of age–matched groups is a limitation of 
the present study, repeating the cortical thickness analysis in smaller (n=22) but age–matched 
groups of 39–48 year–olds yielded similar results (Supplementary Fig. 3). Although the 
significance (expectedly) diminished, the results were consistent with the full group analysis 
suggesting that they were not spurious and, in turn, making it very unlikely that the whole 
group results were merely driven by between–group age differences. Three individuals in the 
PIB-negative group were diagnosed with dementia (n=2/3) or cognitive decline (n=1/3) albeit 
having no evidence of amyloidosis in PIB-PET. Diagnosing dementia in people with 
intellectual disabilities (including DS) is a challenge with an acknowledged risk of 
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uncertainty, particularly exacerbated by the presence of underlying intellectual disability, 
frequent lack of information about individual’s premorbid level of functioning and 
difficulties in communication and therefore heavy reliance on informant opinion (Burt et al., 
1998; for discussion see Annus et al., 2016). Furthermore, changes associated with amyloid 
deposition in DS are described using a cross–sectional dataset. While longitudinal studies are 
needed to understand better the relationship between sub/cortical atrophy and amyloidosis, 
the present findings have highlighted that, in the presence of confirmed amyloidosis, the 
pattern of cortical thinning is similar across AD regardless of aetiology. Finally, it will be of 
interest in future studies with greater power to examine the severity of atrophy stratified not 
just for amyloidosis, but also with respect to clinical status (i.e. stable cognition/cognitive 
decline/dementia); in the present cohort (see Table 1) such a stratification resulted in groups 
that were too small to reliably address this issue. 
5 Conclusion 
This study is the first to describe the cortical landscape of the adult DS brain in distinct 
neuropathologically defined groups. Adults with DS presented with significant 
neuroanatomical differences from typically developing controls, which were further 
exacerbated in those individuals with evidence of amyloid pathology on a PIB PET scan. In 
the absence of amyloid, people with DS had smaller brain volume but with atypically thicker 
cortex in the frontal and occipitoparietal cortices and thinner motor cortex and temporal pole 
compared to controls. The data also demonstrated that, compared to the general population, 
people with DS had disproportionately larger putamina and smaller hippocampi, likely a 
result of abnormal brain development and maturation. In the presence of amyloidosis, adults 
with DS demonstrated posterior dominant cortical thinning as well as atrophy in the 
hippocampi, thalami and the striatum in a strikingly similar pattern as observed in sporadic 
and familiar AD. The data further showed that people with DS can tolerate significant 
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cortical atrophy in the presence of amyloid without deleterious effects on their cognitive 
function.  The present study has highlighted the importance of first understanding the 
neuroanatomical characteristics of the DS brain before any assessments of the effects of 
amyloid are undertaken. Thus, care must be taken when characterising amyloid–related 
structural changes in individuals with DS to avoid underestimation of the observed 
morphology due to disproportionate size of some deep grey matter structures and increased 
thickness of the cortex.  
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Tables 
Table 1. Participant demographics 
 Controls PIB–negative PIB–positive 
PIB–positive 
excl. 3 non-
CAMCOG 
participants 
n, f/m 30, 14/16 27, 13/14 19, 8/11 16, 6/10 
Age, range (years) 
46.2 ± 9.7, 
30–64 
37.1 ± 6, 
28–48 
49.7 ± 6.5, 
39–65 
48.1 ± 5.1, 
39 – 56 
Global cortical 
thickness (mm) 
2.57 ± 0.09 2.68 ± 0.10 2.55 ± 0.12 2.56 ± 0.12 
TIV (cm3) 
1,421.71 ± 
140.58 
1,178.71 ± 
103.13 
1,203.40 ± 
124.10 
1,203.03 ± 
115.00 
TIV–corrected 
TBV* (cm3) 
1,151.26 ± 59.52 1,148.86 ± 29.87 1,067.08 ± 72.05 
1,070.26 ± 
73.94 
Stable cogn./Cogn. 
decline/ Dement. 
N/A 24 / 1 / 2 7 / 5 / 7 7 / 5 / 4 
CAMCOG score 
(max 109), range 
N/A 76, 38 – 102 - 74, 17 – 95 
ApoE†        ε2/ε3 N/A 4 3 2 
                   ε3/ε3 N/A 15 6 6 
                   ε3/ε4 N/A 4 6 6 
                   ε2/ε4 N/A 1 1 1 
Table 1 Data is shown as mean ± standard deviation and range, if applicable. f/m – 
females/males ratio; N/A – not applicable; Stable cogn. – Stable cognition; Cogn. decline – 
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Cognitive decline; Dement. – Dementia; TIV – Total intracranial volume; TBV – Total brain 
volume; ApoE – apolipoprotein E allele. * (Jack et al., 1989). † Three individuals in the PIB–
negative group and three in the PIB–positive group did not undergo ApoE genotyping. 
 
Figure captions 
Figure 1 The cortical signature of the Down syndrome brain without amyloid 
pathology: regional variations in cortical thickness across the hemispheres in the PIB–
negative group (n=27) in comparison to control group (n=30). The colour scale on the right 
represents the significance of the thickness difference as –log10(p–value) with red-yellow 
indicating thinner cortex and blue-light blue indicating thicker cortex in the PIB–negative 
group relative to controls. The results are false-discovery rate corrected at p<0.05. 
Figure 2 The cortical signature of the Down syndrome brain with amyloid pathology: 
regional variations in cortical thickness in the PIB–positive group (n=19), when compared to 
PIB–negative group (n=27). The colour scale on the right represents the significance of the 
difference in thickness as –log10(p–value) with red–yellow indicating thinner cortex and 
blue-light blue indicating thicker cortex in the PIB–positive group relative to PIB–negative 
group. The results are false-discovery rate corrected at p<0.05.  
Figure 3 Volumes of the deep grey matter structures and total brain in the control, PIB–
negative and PIB–positive groups. Unfilled circles in the PIB–positive group represent the 
three individuals who had too advanced dementia to be able to perform the CAMCOG 
cognitive assessment. Figure legend: *** – p<0.001, * – p<0.05, NS – non–significant. All 
tests are two sample t–test results (two-tailed) following one–way ANOVA. 
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Highlights 
 
• Adults with Down syndrome have neurodevelopmentally distinct cortical anatomy. 
• Frontal cortices are atypically thicker with large putamina and small hippocampi. 
• Amyloidosis is associated with posterior cortical thinning and subcortical atrophy. 
• Pattern of cortical thinning resembles Alzheimer’s disease in general population. 
• Care must be taken in assessing amyloid-related structural changes in Down 
syndrome. 
